drugset / Trial / NCT06407232
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.
Timeline
- Start
- 2024-08-08
- Primary completion
- 2027-08
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Letermovir | Small molecule | 480 mg | Oral |